Mac Overmyer
Minimally invasive RPLND safe, efficacious in testis cancer
Minimally invasive retroperitoneal lymph node dissection in testicular cancer reduces length of stay while obtaining a perioperative safety profile comparable to that seen with the open procedure, researchers from the University of California, San Diego Health System reported.
MRI allows visualization of prostate microarchitecture
A group of researchers at Cornell University's Weill Medical College, New York is using magnetic resonance imaging technology at 7 Tesla to obtain prostate tissue images whose resolution rivals that seen with hematoxylin and eosin (H&E) stains.
Effect of prostate cancer recurrence on mortality depends on risk
Men with low-risk prostate cancer have good mortality prospects even when they experience early biochemical recurrence following radical prostatectomy, according to the results of an Australian study.
Cytokine response implicated in uropathogenic E. coli infection
Researchers at Northwestern University in Chicago are exploring the complex web woven by cytokines in uropathogenic Escherichia coli bladder infections and in so doing, are opening avenues for potential therapies for these infections.
Antiandrogen shows efficacy in elderly men with advanced prostate cancer
Bicalutamide monotherapy in men with locally advanced or metastatic prostate cancer is as initially effective as LHRH analogs but can be far more beneficial in preserving bone mineral density, muscle tone, sexual function, and quality of life, say British researchers.
Biomarkers correlate with kidney tumor aggressiveness
High quantities of aberrantly expressed genes are predictive of tumor aggressiveness and poor oncologic outcomes in patients with clear cell renal cell carcinoma, according to a recent study.
Prostate cancer recurrence may be reduced by folic acid
A study from Duke University, Durham, NC suggests that folic acid may reduce the risk of prostate cancer recurrence following radical prostatectomy.
Agent delays bone metastases in men with castration-resistant prostate cancer
The RANK ligand inhibitor denosumab (XGEVA) may be able to prevent or at least delay multiple and/or symptomatic bone metastases in men with castration-resistant prostate cancer (CRPC) at high risk of bone metastases.
Kidney cancer risk could be raised by metabolic syndrome
A study from Weill Cornell Medical College, New York suggests patients with metabolic syndrome may be at increased risk for clear cell renal cell carcinoma.
Prostate cancer survival significantly improved with novel radiation agent
Interim data from a phase III trial of a novel radiation agent in men with castration-resistant prostate cancer (CRPC) showed the agent's efficacy to be significantly sufficient to bring the trial to a halt at a planned interim analysis so as to be able offer the agent to men in the placebo arm.